Evidence map›Paper›PMID 26451726›Full record

Trial reportPloS one2015

Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements.

Akira Obana, Masaki Tanito, Yuko Gohto, Shigetoshi Okazaki, Werner Gellermann, Paul S Bernstein

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04676126 (Augmented Macular Pigment Supplement and Pericentral Visual Function), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04676126 phase4withdrawnnot on this mapstarted 2021, after this paper: background citation

Augmented Macular Pigment Supplement and Pericentral Visual Function: a Randomized Controlled Trial

TypeinterventionalSponsorUniversity of the Incarnate WordRan2021 to 2022Enrolled0ConditionsGlaucoma, Glaucoma Eye, Glaucoma, Open-AngleArmsLumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Effects of MacuprevAdvances in therapy · 2019
    Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Comparing 2-dimensional macular pigment optical density with objective and subjective perimetry and visual acuity in age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Akira ObanaDepartment of Ophthalmology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan; Department of Medical Spectroscopy, Applied Medical Photonics Laboratory, Medical Photonics Research Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Masaki TanitoDepartment of Ophthalmology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.
Yuko GohtoDepartment of Ophthalmology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
Shigetoshi OkazakiDepartment of Medical Spectroscopy, Applied Medical Photonics Laboratory, Medical Photonics Research Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Werner GellermannDepartment of Physics and Astronomy, University of Utah, Salt Lake City, Utah, United States of America.
Paul S BernsteinDepartment of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
Hamamatsu University School of Medicine · JPUniversity of Utah · USSeirei Hamamatsu General Hospital · JPShimane University · JP

Funding

University of Utah, Core Vision Research GrantP30EY014800 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Bryan William Jones · 2005 to 2026
$14.6M
Biochemistry and Pharmacology of the Macular CarotenoidsR01EY011600 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI BERNSTEIN, PAUL STEVEN · 2004 to 2025
$7.7M
BIOCHEMISTRY AND PHARMACOLOGY OF THE MACULAR CAROTENOIDSR29EY011600 · NEI · UNIVERSITY OF UTAH · PI BERNSTEIN, PAUL STEVEN · 1997 to 2001
$209k
NEI NIH HHS EY11600NEI NIH HHS EY14800NEI NIH HHS P30 EY014800NEI NIH HHS R01 EY011600NEI NIH HHS R29 EY011600
6 · The paper itself

Abstract

purposeTo investigate macular pigment optical density (MPOD) and serum concentration changes of lutein in Japanese subjects participating in a clinical trial in which two formulations of lutein and zeaxanthin supplements with different physiochemical properties are used.

methodsThirty-six healthy volunteers were recruited into this prospective, randomized, parallel-group, double-masked comparative study at a single institute. Two products were used, FloraGLO® (Kemin Japan) and XanMax® (Katra Phytochem). The lutein particle size and zeaxanthin concentrations differed between the formulations. The subjects consumed one of the two supplements for a duration of up to 6 months. MPOD levels were measured by resonance Raman spectrometry at baseline and once a month until the end of the study. Serum lutein concentration was measured at baseline, month 3, and month 6. The subjects were also tested for contrast sensitivity, glare sensitivity, visual acuity, and in addition had a focal electroretinogram measured.

resultsThe mean serum lutein concentrations increased significantly after the first three months, but the mean MPOD levels in either supplement group did not show any statistically significant increase. A detailed analysis, however, revealed three response patterns in both groups for the increase of MPOD levels and serum lutein concentration, i.e. "retinal responders", who had an increase of both MPOD levels and serum lutein concentrations (n = 13), "retinal non-responders", who had only increased serum concentrations and no change in MPOD levels (n = 20), and "retinal and serum non-responders", who had neither MPOD level nor plasma concentration increases (n = 3). The subjects with low MPOD levels at baseline appeared to show increased MPOD levels at the 6 month time point upon lutein supplementation (r = -0.4090, p = 0.0133). Glare sensitivity improved in retinal responders in both supplement groups, while there were no remarkable changes in contrast sensitivity.

conclusionsNo statistically significant differences could be detected for MPOD levels and serum lutein concentrations between the two investigated lutein supplement formulations. Responses to lutein supplementation regarding MPOD levels and serum lutein concentrations varied between subjects. Subjects with lower MPOD levels at baseline responded well to lutein supplementation. However, since the number of subjects was low, a further study with more subjects is needed to prove that subjects with low MPOD levels will benefit from lutein supplementation.

trial registrationUMIN-CTR UMIN000004593.

Indexed as

Dietary SupplementsAdultContrast SensitivityFemaleHumansJapanLuteinMacular DegenerationMacular PigmentMaleMiddle AgedProspective StudiesVisual AcuityZeaxanthinsLuteinMacular PigmentZeaxanthins

Identifiers

PMID26451726
PMCPMC4599964
OpenAlexW1936058215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.